Abstract:Abstract Abstract 126 We previously reported that CKS1B may influence myeloma (MM) cell growth and survival through SKP2/p27Kip1-dependent and -independent mechanisms. However, there is still no direct evidence to prove that CKS1B has a role in MM cell proliferation and disease progression. The present study was performed to establish its functional role and define CKS1B-mediated SKP2/p27Kip1-independent down-stream signaling pathways. CKS1B was over-expressed in OCI-MY5 and XG1 MM cell lines by lentivirus. Western blots confirmed CKS1B over-expression. Cells were cultured in medium containing 1% fetal bovine serum for 7 days. CKS1B-transfection resulted in increased cell proliferation compared to empty-vector (EV)-transfected controls. We also examined the role of CKS1B in myeloma resistance to the general used chemotherapeutic drugs, such as bortezomib (5nM), doxorubicin (100nM) and etoposide (100nM). Untreated cells and empty-vector (EV)-transfected cells with or without drug treatments served as controls. Significant less inhibition of cell growth and cell death was observed after drug treatment in CKS1B-transfected cells compared with controls (P < .05). To screen down-stream signaling pathways associated with cell growth and survival in OCI-MY5, MS28PE and XG-1 cells were transfected with specific CKS1B-shRNA, which resulted in decreased phosphorylation of MEK1/2, ERK1/2, STAT3, MCL1 and BCL2 compared to wild-type and control cells, transfected with scrambled CKS1B-shRNA. To confirm these results, we examined the alteration of STAT3, MEK/ERK and BCL2 signaling pathways in OCI-MY5 and XG1 cells after forced over-expression of CKS1B. Increased levels of p-MEK1/2, p-ERK1/2, p-STAT3, MCL1 and p-BCL2 were observed compared to the EV-transfected controls, confirming that CKS1B activates STAT3, MEK/ERK and BCL2 signaling pathways. In Contrast, SKP2 over-expression or p27Kip1 inhibition resulted in inhibition of STAT3 and MEK/ERK pathways with no remarkable changes inBCL2. Further investigation showed that BCL2 is a downstream target of MEK/ERK signaling. Stimulation of STAT3, MEK/ERK and BCL2 signaling pathways only partially abrogated MM cell death and growth inhibition induced by CKS1B knockdown. Targeting either the STAT3, MEK/ERK or BCL2 signaling pathway with specific inhibitors induced significant MM cell death and growth inhibition in CKS1B-over-expressing MM cells; their combination had a synergistic effect on cell death and growth inhibition. Our findings provide a rationale for targeting STAT3 and MEK/ERK/BCL2 signaling in the therapy of aggressive CKS1B-overexpressing MM, which shows increased proliferation and drug-resistance Disclosures: No relevant conflicts of interest to declare.

CAMKIIγ is a Targetable Driver of Multiple Myeloma Through CaMKIIγ/ Stat3 Axis

N6-methyladenosine-induced miR-182-5p promotes multiple myeloma tumorigenesis by regulating CAMK2N1

CD229 interacts with RASAL3 to activate RAS/ERK pathway in multiple myeloma proliferation

CAMK2γ Antagonizes Mtorc1 Activation During Hepatocarcinogenesis.

CAMK2γ in Intestinal Epithelial Cells Modulates Colitis-Associated Colorectal Carcinogenesis Via Enhancing STAT3 Activation

Mk2 Is A Therapeutic Target For High-Risk Multiple Myeloma

Aberrant Activation of CaMKIIγ Accelerates Chronic Myeloid Leukemia Blast Crisis.

Ca2+/calmodulin-dependent protein kinase IIγ enhances stem-like traits and tumorigenicity of lung cancer cells.

Targeting CaMKII-δ/DHCR24 Axis is a Novel Strategy Against Acute Myeloid Leukemia

Interleukin-32 Alpha Promotes The Proliferation Of Multiple Myeloma Cells By Inducing Production Of Il-6 In Bone Marrow Stromal Cells

Targeting CLK2 and serine/arginine‐rich splicing factors inhibits multiple myeloma through downregulating RAE1 by nonsense‐mediated mRNA decay mechanism

Interleukin-6 Drives Multiple Myeloma Progression by Up-Regulating of CD147/Emmprin Expression

IMMU-34. CAMKK2 PROMOTES AN IMMUNOSUPPRESSIVE PROGRAM AND CHECKPOINT BLOCKADE RESISTANCE IN THE GLIOBLASTOMA TUMOR MICROENVIRONMENT

CaMKK2 deletion increases antitumor potential through enhanced MHC-II expression in Macrophages

Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance.

Camkii Gamma, A Critical Regulator Of Cml Stem/Progenitor Cells, Is A Target Of The Natural Product Berbamine

MAPK Cascade Signaling is Involved in Α-Mmc Induced Growth Inhibition of Multiple Myeloma MM.1S Cells Via G2 Arrest and Mitochondrial-Pathway-Dependent Apoptosis in Vitro.

Cks1b Mediates Skp2/P27kip1-Independent Myeloma Cell Survival And Disease Progression Through Activation Of Mek/Erk And Jak/Stat3 Signaling Pathways

TTK Promotes Multiple Myeloma Progression by Regulating RGN Expression

CXCL10 recruitment of γδ T cells into the hypoxic bone marrow environment leads to IL-17 expression and multiple myeloma progression

Calcium/Calmodulin Dependent Protein Kinase Kinase 2 Regulates the Expansion of Tumor-Induced Myeloid-Derived Suppressor Cells